| Followers | 223 |
| Posts | 15358 |
| Boards Moderated | 4 |
| Alias Born | 03/25/2006 |
Wednesday, May 04, 2022 9:11:12 AM
Yep - this will be a hold for me as well. Far too much potential in the field of medicine they are in for this to remain this low in price for very long.
The reason for global warming is because hell is getting hotter.
Recent ACON News
- Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain • GlobeNewswire Inc. • 04/16/2026 10:47:04 AM
- Aclarion Receives Pinnacle Award for AI Innovation • GlobeNewswire Inc. • 04/14/2026 12:00:00 PM
- Aclarion Announces Agreement with Weill Cornell Medicine • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video • GlobeNewswire Inc. • 04/07/2026 12:00:00 PM
- Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc. • ACCESS Newswire • 03/24/2026 12:00:00 PM
- Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan • GlobeNewswire Inc. • 03/19/2026 01:25:40 PM
- Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts • GlobeNewswire Inc. • 03/19/2026 10:00:00 AM
- Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet • GlobeNewswire Inc. • 03/17/2026 10:00:00 AM
- Aclarion CEO Brent Ness to Attend LSI USA 2026 • GlobeNewswire Inc. • 03/12/2026 10:00:00 AM
- Aclarion Publishes 2026 Shareholder Letter from the Chairman • GlobeNewswire Inc. • 02/05/2026 11:00:00 AM
- Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation • GlobeNewswire Inc. • 02/03/2026 11:00:00 AM
- Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028 • GlobeNewswire Inc. • 01/13/2026 11:00:00 AM
- Aclarion shares surge after sharp rise in Q4 Nociscan usage • IH Market News • 01/08/2026 03:30:17 PM
- Aclarion Provides 2025 Update and 2026 Corporate Outlook • GlobeNewswire Inc. • 01/08/2026 11:00:00 AM
- Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data • GlobeNewswire Inc. • 01/06/2026 11:00:00 AM
- Aclarion Shares Move Higher After Nociscan Highlighted in Spine Surgery Journal • IH Market News • 12/04/2025 03:58:32 PM
- Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS) • GlobeNewswire Inc. • 12/04/2025 01:00:00 PM
- Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S. • GlobeNewswire Inc. • 12/02/2025 01:00:00 PM
- Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion • GlobeNewswire Inc. • 11/05/2025 11:00:00 AM
- Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH • GlobeNewswire Inc. • 10/22/2025 10:00:00 AM
- Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst • GlobeNewswire Inc. • 10/14/2025 10:09:47 AM
- Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference • GlobeNewswire Inc. • 10/13/2025 10:00:00 AM
- Aclarion to Present at the LD Micro Main Event XIX • Newsfile • 10/09/2025 10:00:00 AM
- Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH • GlobeNewswire Inc. • 10/07/2025 10:00:00 AM
- Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers • GlobeNewswire Inc. • 10/01/2025 11:17:53 AM
